Iovance Biotherapeutics, Inc. IOVA EBITDA

EBITDA at other companies

Bristol-Myers SquibbBMY

$4.68B+68.1%

Gilead SciencesGILD

-$10.3B-501%

ImmunityBio, Inc.IBRX

-$65.41M-7.9%

Cullinan Therapeutics, Inc.CGEM

-$57.18M+24.5%

Artiva Biotherapeutics, Inc.ARTV

-$26.2M-18.2%

IncyteINCY

$724.37M+30.9%

FAQ

What is Iovance Biotherapeutics, Inc.'s EBITDA?

Iovance Biotherapeutics, Inc. (IOVA) reported EBITDA of -$48.12M in Q2 2026.

How has Iovance Biotherapeutics, Inc.'s EBITDA changed year-over-year?

Iovance Biotherapeutics, Inc.'s EBITDA increased by 56.4% year-over-year, from -$110.37M to -$48.12M.

What is the long-term trend for Iovance Biotherapeutics, Inc.'s EBITDA?

Over 4 years (2021 to 2025), Iovance Biotherapeutics, Inc.'s EBITDA has grown at a 3.6% compound annual growth rate (CAGR), from -$339.59M to -$390.47M.

What does EBITDA mean?

Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.